IVF · XBRL financial data
INVO Fertility financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (IVF's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 1,037 | — | — | 3,021 | 6,532 | 6,841 |
| Revenue from contracts with customers | 1,037 | 4,160 | 822 | 3,021 | 6,561 | — |
| Cost of revenue | 89 | 145 | 332 | 1,973 | 3,717 | — |
| Cost of goods and services sold | 79 | 126 | 287 | — | 12 | 31 |
| Gross profit | 949 | 4,015 | 491 | — | — | — |
| Research and development | 398 | 216 | 544 | 166 | 490 | — |
| Selling, general and administrative | 6,065 | 9,015 | 10,573 | 7,486 | 9,079 | 7,691 |
| General and administrative | — | — | — | 704 | 2,400 | — |
| Total operating expenses | 6,463 | 9,232 | 11,117 | 9,788 | 14,657 | — |
| Operating income (loss) | (5,515) | (5,217) | (10,626) | (6,767) | (8,125) | (7,237) |
| Interest income | 4 | — | — | — | — | — |
| Interest expense | 2,837 | 1,265 | 59 | 926 | 1,056 | 1,302 |
| Income tax expense (benefit) | 0 | 5 | 3 | 28 | (23) | (150) |
| Net income (loss) | (8,347) | (6,655) | (10,893) | (8,035) | (9,096) | (23,323) |
| Earnings per share, basic USD per share | (1.52) | (0.63) | (0.90) | (5.13) | (30.19) | (214.64) |
| Earnings per share, diluted USD per share | (1.52) | (0.63) | (0.90) | (5.13) | (30.19) | (214.64) |
| Weighted average shares, basic thousands of shares | 5,490 | 10,632 | 12,123 | 1,566 | 310 | 117 |
| Weighted average shares, diluted thousands of shares | 5,490 | 10,632 | 12,123 | 1,566 | 310 | 117 |
- † Share count changed about 1/5 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (IVF's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 10,098 | 5,685 | 90 | 232 | 741 | 2,078 |
| Accounts receivable | 22 | 50 | 77 | 141 | 175 | 217 |
| Inventory | 265 | 288 | 264 | 265 | 220 | 225 |
| Prepaid and other current assets | 158 | 283 | 190 | 622 | 182 | 241 |
| Total current assets | 10,543 | 6,306 | 621 | 1,260 | 1,318 | 2,762 |
| Property and equipment, net | 132 | 501 | 437 | 826 | 467 | 386 |
| Right-of-use asset | 79 | 2,037 | 1,808 | 3,359 | 2,284 | 1,286 |
| Goodwill | — | — | — | 5,879 | 23,536 | 5,879 |
| Total assets | 10,947 | 10,466 | 4,104 | 18,506 | 46,449 | 20,220 |
| Accounts payable | 329 | — | — | — | — | — |
| Current portion of long-term debt | — | — | — | — | 6,338 | 1,275 |
| Total current liabilities | 2,288 | 1,253 | 3,409 | 8,003 | 17,926 | 10,332 |
| Long-term debt | — | — | — | — | 1,129 | 745 |
| Lease liability, non-current | 59 | 1,902 | 1,670 | 3,356 | 2,190 | 1,171 |
| Total liabilities | 5,204 | 3,156 | 5,081 | 17,613 | 26,245 | 12,996 |
| Accumulated deficit | (32,236) | (38,891) | (49,784) | (57,818) | (67,165) | (91,369) |
| Total stockholders' equity | 5,743 | 7,311 | (978) | 893 | 12,747 | 7,224 |
| Total liabilities and equity | 10,947 | 10,466 | 4,104 | 18,506 | 46,449 | 20,220 |
| Common shares outstanding (cover page) thousands of shares | 10,420 | 12,089 | 13,971 | 2,743 | 1,066 | 1,786 |
- † Share count changed about 1/5 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (IVF's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (8,347) | (6,655) | (10,893) | (8,035) | (9,096) | (23,323) |
| Stock-based compensation | 1,141 | 1,544 | 1,616 | — | — | 163 |
| Depreciation and amortization | 12 | 28 | 77 | 201 | 920 | 677 |
| Net cash from operating activities | (4,775) | (6,030) | (6,603) | (4,755) | (2,974) | (7,014) |
| Purchases of property and equipment | 49 | 416 | 11 | 445 | 184 | 43 |
| Net cash from investing activities | (187) | (2,154) | (81) | (2,495) | 364 | (2,745) |
| Proceeds from issuing common stock | 11,475 | 3,651 | 290 | 5,702 | 165 | 12,356 |
| Proceeds from issuing equity | — | — | 800 | 3,200 | 1,300 | — |
| Net cash from financing activities | 13,822 | 3,771 | 1,090 | 7,392 | 3,119 | 11,096 |
| Net change in cash | 8,859 | (4,413) | (5,595) | 142 | 509 | 1,336 |
- † Share count changed about 1/5 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| INVO Fertility | 3,733 | 2,175 | (1,101)* | 2.5M | 3.4 quarters | 10-QJun 30, 2026 |
| LogicMark | 3,496 | 3,349 | 83* | 899,759 | — | 10-QJun 30, 2026 |
| Stimcell Energetics | 6.9 | not reported | (109) | 21.1M | 0.1 quarters | 10-QAug 31, 2026 |
| Bluejay Diagnostics | 9,599 | not reported | (1,499)* | 4.5M | 6.4 quarters | 10-QJun 30, 2026 |
| Interpace Biosciences | 2,688 | 9,131 | 98* | 27.7M | — | 10-QJun 30, 2026 |
| Global Innovative Platforms | 244 | 51 | (134)* | 49.8M | 1.8 quarters | 10-QJun 30, 2026 |
| ENDRA Life Sciences | 1,740 | not reported | (928)* | 1.5M | 1.9 quarters | 10-QJun 30, 2026 |
| Vycor Medical | 159 | 418 | (4.8)* | 33.4M | 32.8 quarters | 10-QJun 30, 2026 |
| QHSLab | 317 | 847 | (7.8)* | 15.0M | 40.6 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.